Latest MicroRNA Stories

A University of Colorado Cancer Center study recently published in the journal Cell Death & Disease shows that turning up a few microRNAs a little may offer as much anti-breast-cancer activity as turning up one microRNA a lot – and without the unwanted side effects. It’s a bit like the classic thought experiment known as the “tumor problem” formulated by Karl Dunker in 1945 and used frequently in the problem-solving literature: Imagine a person suffers from a malignant tumor in...

Researchers at the University of Illinois have identified biomarkers that can be used to determine ovarian cancer survival and recurrence, and have shown how these biomarkers interact with each other to affect these outcomes. Their findings appear in the journal PLOS ONE. Researchers try to find molecules called biomarkers that help determine a person’s likelihood of getting a disease or, if they have already been diagnosed, how far the disease has advanced. Genes, transcription...

-Determining a breast-cancer patient’s prognosis can be difficult because breast tumors contain many genetic differences and there are many subtypes; -This study combined and analyzed large masses of data from 466 cases of the most common type of breast cancer; -The study identified a small group of molecules that might predict breast-cancer prognosis across many subtypes of the disease and at its early stages; -For the first time a prognostic signature in cancer is composed of both mRNA...

Neurons in the nose could be the key to early, fast, and accurate diagnosis, says a TAU researcher A debilitating mental illness, schizophrenia can be difficult to diagnose. Because physiological evidence confirming the disease can only be gathered from the brain during an autopsy, mental health professionals have had to rely on a battery of psychological evaluations to diagnose their patients. Now, Dr. Noam Shomron and Prof. Ruth Navon of Tel Aviv University's Sackler Faculty of...

Researchers at the University of Bonn decode a kind of trigger switch for the conversion of fat cells For a long time, scientists have dreamt of converting undesirable white fat cells into brown fat cells and thus simply have excess pounds melt away. Researchers at the University of Bonn have now gotten a step closer to this goal: They decoded a "toggle switch" in mice which can significantly stimulate fat burning. The results are now being presented in the scientifc journal "Nature...

An international research team including Christian Schlötterer and Alistair McGregor of the Vetmeduni Vienna has discovered a completely new mechanism by which evolution can change the appearance of an organism.  The researchers found that the number of hairs on flies’ legs varies according to the level of activity of a so-called microRNA.  The results, published in the journal Current Biology, shed a completely new light on the molecular mechanisms of evolution. It has long been...

HOERSHOLM, Denmark and SAN DIEGO, April 18, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the EPO has issued Minutes of the Oral Proceedings specifying the Board of Appeal's decision to maintain EP 1015469, the "Wengel" patent, with the claims to amino- and thio-LNA nucleotides and oligonucleotides. (Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO)...

HOERSHOLM, Denmark and SAN DIEGO, April 5, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the USPTO issued an Inter Partes Reexamination Certificate for U.S. Pat. No. 6,770,748 (the '748 patent) on April 1, 2013. The certificate, which follows a decision by the USPTO to dismiss an appeal that had been filed by Isis Pharmaceuticals during the proceeding,...

microRNA-based diagnostic assays for classifying renal cell tumors and for classifying tumors from patients with cancer of unknown or uncertain primary to be featured in poster session on April 7 PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company's microRNA-based diagnostic assays will be featured at the...

-- Final Phase 2a results show dose-dependent, prolonged antiviral activity in Hepatitis C patients -- HOERSHOLM, Denmark and SAN DIEGO, March 27, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the publication of study results online in the New England Journal of Medicine (NEJM). The publication highlights the potential benefits of miravirsen, a host-targeted,...